News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Chugai Pharmaceutical Co., Ltd. (Japan)'s Bispecific Antibody "ACE910" For The Treatment Of Hemophilia A Designated As A Breakthrough Therapy By The FDA 9/4/2015
AstraZeneca PLC (AZN) To Update On Leading Lung Cancer Portfolio At WCLC 2015 9/4/2015
Coherus Provides Updates On Clinical Studies 9/4/2015
Oramed (ORMP) To Present At The Rodman & Renshaw Global Investment Conference 9/4/2015
DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results And Provides Corporate Update 9/4/2015
Hutchison China MediTech (Chi-Med) Release: Second Proof-Of-Concept Trial Of Fruquintinib Achieves Its Primary Endpoint 9/4/2015
Atopix Appoints Dr Andrew Zambanini As Chief Medical Officer 9/3/2015
HUYA Bioscience International Announces Epigenetic Breast Cancer Program 9/3/2015
City of Hope Release: Trial Of Telomerase Inhibitors Points To Lasting Treatments For Myeloproliferative Disorders 9/3/2015
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 To Enter Phase 2 Clinical Studies In Atopic Dermatitis And Celiac Disease In US And Europe 9/3/2015
Cerecor Inc. Initiates Phase II Study For CERC-301, An Antidepressant Product Candidate With Potential For Rapid Onset Of Effect 9/3/2015
Dermira To Present Data For DRM01 Acne Program At 45th Annual ESDR Meeting 9/3/2015
InSite Vision (ISV) Announces New Date For Special Stockholder Meeting 9/3/2015
Bristol-Myers Squibb (BMY) To Present New Data From Its Immuno-Oncology Clinical Development Programs At 16th World Conference On Lung Cancer 9/3/2015
Cytori Therapeutics, Inc. (CYTX) To Provide Corporate Update And Investor Presentation Live, At VirtualInvestorConferences.com September 10 9/3/2015
CytRx Corporation (CYTR) Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado 9/3/2015
Geron Corporation (GERN) Release: Dual Publications In The New England Journal of Medicine Highlight Transformative Potential Of Imetelstat In Hematologic Myeloid Malignancies 9/3/2015
MediciNova, Inc. Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled In Phase II Clinical Trial Of MN-166 (Ibudilast) 9/3/2015
Celsion Corporation (CLSN) To Present At The Rodman & Renshaw 17th Annual Global Investment Conference 9/3/2015
Helsinn Group Signs Exclusive Agreement With Munipharma For The Distribution And Licence Of Anamorelin In Switzerland And Liechtenstein 9/3/2015
Thrasos To Present At The 22nd Annual BioCentury NewsMakers And 8th Annual Biopharm America Conferences 9/2/2015
Aurinia (ISA.TO) To Present At The 2015 Rodman & Renshaw 17th Annual Global Investment Conference 9/2/2015
ImmusanT, Inc. Release: Journal Gastroenterology Publishes Research Indicating Nearly Identical Response To Gluten In Most Children And Adults With Celiac Disease 9/2/2015
Spectrum Pharmaceuticals, Inc. (SPPI) Announces Publication Of Pivotal EVOMELA (Melphalan Hydrochloride) For Injection Data In The Biology Of Blood And Marrow Transplantation Journal 9/2/2015
Catabasis Pharmaceuticals, Inc. To Participate In The Citi 10th Annual Biotech Conference And Present At The NewsMakers In The Biotech Industry Conference 9/2/2015
ArmaGen Technologies, Inc. Announces First Patient Dosed In Phase 1/2a Clinical Trial Of AGT-181 For The Treatment Of Hurler Syndrome 9/2/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) To Present At Rodman & Renshaw Global Investment Conference 9/2/2015
TapImmune Inc. (TPIV) To Present At 17th Annual Rodman & Renshaw Healthcare Conference 9/2/2015
OncoSec Medical Inc. To Present At Scientific And Investment Conferences In September 9/2/2015
ContraVir Pharmaceuticals To Present At Rodman & Renshaw 17th Annual Global Investment Conference 9/2/2015
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports Fiscal Year 2015 Results 9/2/2015
Neurotech Announces First Patient Enrolled In Novel Anti-VEGF Encapsulated Cell Therapy Study 9/2/2015
Intra-Cellular Therapies, Inc. Announces Publication Of Positive Phase II Schizophrenia Study In The Journal Biological Psychiatry 9/2/2015
BiondVax Pharmaceuticals Announces Intent To Launch A Phase 2 Trial In The United States In Collaboration With The U.S. NIH 9/2/2015
Flexion (FLXN) Granted Fast Track Status By The FDA For FX006 For Treatment Of Osteoarthritis Of The Knee 9/2/2015
DelMar Pharmaceuticals Announces Expansion Of VAL-083 Development Program To Include Ovarian Cancer 9/2/2015
Sangamo BioSciences (SGMO) And Shire (SHPG) Restructure Collaboration To Accelerate Development Of ZFP Therapeutics For The Treatment Of Hemophilia And Huntington's Disease 9/2/2015
Michael Meyers, M.D., Ph.D., Joins Syndax As SVP And Chief Development Officer 9/1/2015
BioTime (BTX) Chief Executive Officer Dr. Michael D. West To Be Keynote Speaker At Stem Cells & Regenerative Medicine Congress 2015 9/1/2015
ERYtech Pharma Appoints Eric Soyer As Chief Financial And Chief Operating Officer 9/1/2015
BioTime (BTX) Subsidiary Asterias Biotherapeutics Concludes Recruitment Of Initial Safety Cohort Of The SCiStar Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 9/1/2015
Trevena, Inc. (TRVN) Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain 9/1/2015
MicuRx Pharmaceuticals Says Novel Antibiotic Passes China Phase II Test 9/1/2015
Viking Therapeutics (VKTX) Initiates Clinical Trial For VK5211, A Selective Androgen Receptor Modulator (SARM), For Acute Hip Fracture 9/1/2015
Ultragenyx (RARE) Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin 9/1/2015
XTL Biopharmaceuticals Ltd. (XTLB) Reports Second Quarter 2015 Results 9/1/2015
MediWound (MDWD) Completes Enrollment In Second Phase II Clinical Trial Of Escharex To Treat Chronic And Other Hard-To-Heal Wounds 9/1/2015
Neovacs SA Receives First Regulatory Approvals For A Phase IIb Trial Of Ifna-Kinoid In Lupus 9/1/2015
Can-Fite BioPharma (CFBI) To Present At Rodman & Renshaw 17th Annual Global Investment Conference On September 9, 2015 9/1/2015
Corbus Commences Patient Enrollment In Phase 2 Clinical Study Of Resunab For The Treatment Of Systemic Sclerosis 8/31/2015
MabVax Therapeutics, Inc. HuMab 5B1 Antibody Is Highlighted At Upcoming World Molecular Imaging Congress In Five Separate Presentations 8/31/2015
OncoMed Pharmaceuticals, Inc. (OMED) Completes Enrollment Of Phase II ALPINE Clinical Trial Of Tarextumab In Pancreatic Cancer 8/31/2015
Phase II Study Of Advaxis, Inc.'s Axalimogene Filolisbac (ADXS-HPV) In Cervical Cancer To Be Presented At 2015 AGOS Annual Meeting 8/31/2015
Atara Biotherapeutics (ATRA) Announces Completion Of Enrollment In PINTA 745 Phase II Clinical Trial In End-Stage Renal Disease Patients With Protein Energy Wasting 8/31/2015
RXi Pharmaceuticals (RXII) Announces Advancements In Its Ophthalmology Clinical Program With RXI-109 8/31/2015
Regen BioPharma Develops BORIS Gene Silencing Based Treatment For Unresectable Liver Cancer 8/31/2015
Allergan (AGN) Successfully Completes Naurex Acquisition 8/31/2015
MicuRx Pharmaceuticals Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 8/31/2015
Asterias Biotherapeutics Concludes Recruitment Of Initial Safety Cohort Of The SCiStar Phase 1/2a Dose-Escalation Clinical Trial Of AST-OPC1 For Complete Cervical Spinal Cord Injury 8/31/2015
Soligenix (SNGX) Announces Completion Of Patient Enrollment Into Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients (1) 8/31/2015
Ascletis, Inc. Phase II Clinical Trial Of Its Interferon-Free HCV Regimen In Taiwan 8/31/2015
In Response to Twitter Rumors and Phase II Data, Verastem (VSTM) Stock Plunges 8/28/2015
Can-Fite BioPharma (CFBI) Reports Financial Results For Six Months Ended June 30, 2015 8/28/2015
Threshold Pharmaceuticals, Inc. (THLD) Initiates Phase 2 Clinical Trial Of Tarloxotinib Bromide (TH-4000) In Patients With Recurrent Or Metastatic Squamous Cell Carcinomas Of The Head And Neck Or Skin 8/27/2015
Verastem (VSTM) Issues Statement Regarding WCLC Presentations 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
Asterias Biotherapeutics To Present At Upcoming Investor Conferences 8/27/2015
DelMar Pharmaceuticals To Announce Fiscal 2015 Year-End Financial Results On September 4, 2015 8/27/2015
iCo Therapeutics Inc. Announces Second Quarter 2015 Financial Results 8/27/2015
Oncolytics Biotech Inc. (ONC.TO) Collaborators To Present Survival Data From REO 016 Study In Non-Small Cell Lung Cancer 8/27/2015
Janssen Research & Development Release: Data Published In The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated A 36 Percent Overall Response Rate And Tolerable Safety Profile In Heavily Pre-Treated Multiple Myeloma Patients 8/27/2015
Oncoceutics Release: Enrollment Begins In Expansion Phase Of ONC201 Clinical Trial 8/26/2015
Verastem, Inc. (VSTM) To Present Data At The 16th World Conference On Lung Cancer 8/26/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant To Develop Its Proteoglycan Mimetic Therapeutics To Reduce Vascular Access Failures In ESRD 8/26/2015
CryoPort, Inc. Supports Opexa Therapeutics (OPXA)' Lead Personalized T-Cell Immunotherapy Programs 8/26/2015
XTL Biopharmaceuticals Ltd. (XTLB) Announces Publication Of Results Of Phase 2 Study On Hcdr1 (Edratide) In Patients With Active Systemic Lupus Erythematosus (SLE) In Lupus Science & Medicine 8/26/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase II Non-Small Cell Lung Cancer Study 8/26/2015
DelMar Pharmaceuticals To Present At The 17th Annual Rodman & Renshaw Global Investment Conference On September 9, 2015 8/25/2015
CSL Behring Enrolls First Patient In Global Phase II/III Study Of rVIIa-FP For On-Demand Treatment Of Patients With Hemophilia A Or B With Inhibitors 8/25/2015
Arbutus Biopharma (ABUS) Announces Initiation Of Patient Dosing In The TKM-PLK1 HCC Expansion Cohort 8/25/2015
Ascendis Pharma A/S Reports Second Quarter 2015 Financial Results 8/25/2015
Allergan (AGN) And Gedeon Richter Ltd. (RIG2.F) To Present Data From Cariprazine Trials At European College Of Neuropsychopharmacology (ECNP) Annual Meeting In Amsterdam 8/25/2015
Regulus (RGLS) Appoints Michael Huang, M.D. As Vice President, Clinical Development 8/25/2015
Chrono Therapeutics, Inc. Receives Second Fast Track SBIR Grant From National Cancer Institute For Patient-Individualized Smoking Cessation Therapy 8/25/2015
Clementia Expands Ongoing Phase 2 Study To Include Children With Fibrodysplasia Ossificans Progressiva (FOP) 8/25/2015
FDA Grants Orphan Drug Designation For Tocagen Inc.'s Toca 511 & Toca FC, An Investigational Immuno-Oncology Treatment For Glioblastoma 8/25/2015
Regen BioPharma BORIS Gene Silencing Technology Successfully Utilized By Independent Researchers To Kill Breast Cancer And Colon Cancer Stem Cells 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
Esperance Pharmaceuticals, Inc. Announces Strategic Alliance With MD Anderson Cancer Center 8/24/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
OncoSec Medical Inc. Promotes Sheela Mohan-Peterson To Chief Legal And Compliance Officer 8/24/2015
Genentech (RHHBY) Throws Cancers in a Basket to Detect Tumors at Their Genetic Roots 8/21/2015
Seres Therapeutics Announces FDA Orphan Drug Designation For SER-109 For The Prevention Of Recurrent Clostridium Difficile Infection in Adults 8/21/2015
ProNAi Therapeutics, Inc. Reports Second Quarter 2015 Results 8/21/2015
HedgePath Pharmaceuticals Launches Clinical Trial For Its Proposed Cancer Treatment 8/21/2015
Vernalis PLC (VNLPY.PK) Completes Investment In Its NCE Development Pipeline 8/20/2015
60 Degrees Pharmaceuticals To Begin Phase II Clinical Trials In Dengue Fever Patients 8/20/2015
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide In Phase 2 Trial In Osteoarthritis 8/20/2015
The Leukemia & Lymphoma Society Applauds Encouraging Data From A Phase 2 Study Of Venetoclax For A High-Risk Subset Of Chronic Lymphocytic Leukemia Patients 8/20/2015
S1 BioPharma (Formerly Known As S1 Pharmaceuticals, Inc.) Supports FDA Approval Of First-Ever Treatment For Hypoactive Sexual Desire Disorder 8/20/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
Esperion (ESPR) Rockets as Lead Drug ETC-1002 Will Not Require Heart Trial for FDA Approval 8/19/2015
FDA Grants Fast Track Designation To Cempra Pharmaceuticals, Inc. (CEMP) For Solithromycin In The Treatment Of Community Acquired Bacterial Pneumonia 8/19/2015
Corbus' Investigational Drug Resunab Granted Fast Track Status By The U.S. FDA For The Treatment Of Systemic Sclerosis 8/19/2015
Astex Pharmaceuticals (ASTX) Announces Publication Of Key Clinical Data For Guadecitabine (SGI-110) In The Lancet Oncology 8/19/2015
Madison Vaccines Announces Patient Dosing Underway In Clinical Trial Pairing Its Lead Prostate Cancer Vaccine, MVI-816, With PD1 Inhibitor Pembrolizumab 8/19/2015
Genentech (RHHBY)'s Atezolizumab Shrank Tumors in Phase II Lung Cancer Trial 8/18/2015
Esperion (ESPR) Provides Update On The ETC-1002 Development Program Following End-Of-Phase II Meeting With FDA 8/18/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
Remedy Pharmaceuticals, Inc. Initiates Phase IIA Study Of CIRARA In Spinal Cord Injury 8/18/2015
Matinas BioPharma's Lead Antifungal Product Candidate MAT2203 Granted QIDP And Fast Track Designations By FDA 8/18/2015
TapImmune Inc. (TPIV) Completes Transfer of IND From The Mayo Clinic 8/18/2015
Armetheon Expands Leadership Team, Names Detlef Albrecht, M.D., As Chief Medical Officer 8/18/2015
Omeros Corporation (OMER) Announces Additional Positive Data In OMS721 Phase 2 Clinical Trial 8/18/2015
OncoSec Medical Inc. Announces First Patient Enrolled In Phase II Clinical Trial Evaluating Combination Of ImmunoPulse IL-12 And Anti-PD-1 Treatment 8/18/2015
Avalanche Biotech (AAVL) Goes Back to Drawing Board, Performs More Preclinical Studies on Eye Drug 8/17/2015
Pfenex (PFNX) Wins $143.5 Million Next-Gen Anthrax Vaccine Contract 8/17/2015
Prima Biomed (PRR.AX) Announces Commencement Of Milestones For IMP701 Program 8/17/2015
BioLineRx Ltd. Announces Initiation Of Phase 2b Trial For Novel AML Consolidation Treatment 8/17/2015
Invion Limited Completes Clinical Trial Of INV103 (ala-Cpn10) In Lupus Patients 8/17/2015
Immune Pharmaceuticals, Inc. Announces Corporate Update; Second Quarter 2015 Financial Results And Highlights And Conference Call Details 8/17/2015
Amarantus BioSciences, Inc. Reports Second Quarter 2015 Financial Results And Business Overview 8/17/2015
Recro Pharma (REPH) Reports Second Quarter 2015 Financial Results 8/17/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence Multiple Ascending Dose Study With Promising NMDA Receptor Antagonist 8/17/2015
Tobira Therapeutics Inc. Announces Initiation Of ORION, A Phase 2a Study Of Cenicriviroc In Obese Patients With Suspected Fatty Liver Disease 8/17/2015
Cara Therapeutics, Inc. (CARA) Initiates Phase II Trial Of Oral CR845 In Osteoarthritis 8/17/2015
Pivotal Phase II Study Showed Genentech (RHHBY)’s Investigational Immunotherapy Atezolizumab Shrank Tumors In People With A Specific Type Of Lung Cancer 8/17/2015
Ultragenyx (RARE) Reports Second Quarter 2015 Financial Results And Corporate Update 8/14/2015
FibroGen, Inc. (FGEN) Announces Second Quarter 2015 Financial Results 8/14/2015
GlobeImmune (GBIM) Announces Second Quarter 2015 Results And Corporate Highlights 8/14/2015
Addex Therapeutics (ADXN.SW) Dipraglurant Demonstrates Anxiolytic- And Antidepressant-Like Activity In Multiple Preclinical Models Relevant For Non-Motor Symptoms In Parkinson's Disease 8/14/2015
Catabasis Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results And Recent Corporate Highlights 8/14/2015
Bellicum (BLCM) Provides Operational Update And Reports Financial Results For The Second Quarter Ended June 30, 2015 8/14/2015
Sophiris Bio Inc. (SPHS) Reports Second Quarter Financial Results 8/14/2015
CASI Pharmaceuticals  (CASI) Reports Second Quarter 2015 Financial Results 8/14/2015
OncoGenex Pharmaceuticals Inc. (OGXI) Reports Financial Results For Second Quarter 2015 8/14/2015
Genentech (RHHBY), AbbVie (ABBV) Confirm Venetoclax Met Primary Endpoint in Phase II Study 8/13/2015
Juno (JUNO) Reports Second Quarter 2015 Financial Results 8/13/2015
BioLineRx Ltd. To Report Second Quarter 2015 Results On August 20, 2015 8/13/2015
Argos Therapeutics, Inc. (ARGS) Reports Second Quarter 2015 Financial Results And Operational Highlights 8/13/2015
Heat Biologics Announces Financial Results For The Second Quarter Ended June 30, 2015 8/13/2015
Viking Therapeutics (VKTX) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
Opexa Therapeutics (OPXA) Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
VBL Therapeutics (VBLX) Announces Second Quarter 2015 Financial Results And Provides Business Update 8/13/2015
Eleven Biotherapeutics (EBIO) Reports Second Quarter 2015 Financial Results 8/13/2015
Mologen AG (MOLGF.PK): First Half Of 2015 Defined By Study Progress And Capital Increase 8/13/2015
FibroGen, Inc. (FGEN) Release: Nephrology Dialysis Transplantation Reports Phase II Data Of Investigational Orally Active HIF-PHI Roxadustat (FG-4592) Shows Improved Hemoglobin Levels In Non-Dialysis CKD Subjects With Anemia 8/13/2015
BrainStorm Cell Therapeutics Inc. Reports Second Quarter 2015 Financial Results And Provides Corporate Update 8/13/2015
ARCA biopharma Announces Second Quarter 2015 Operating Results And Provides Update On Recent Accomplishments 8/12/2015
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results And Provides Business Update 8/12/2015
Ischemix Elects Peter G. Milner, MD To Board Of Directors 8/12/2015
GenSpera Provides 2nd Quarter Corporate Update 8/12/2015
Viamet To Present At American Chemical Society National Meeting 8/12/2015
Akebia Therapeutics, Inc. (AKBA) Announces Second Quarter 2015 Financial Results 8/12/2015
Aurinia (ISA.TO) Reports Second Quarter 2015 Financial Results 8/12/2015
Exelixis (EXEL) Announces Second Quarter 2015 Financial Results And Provides Corporate Update 8/12/2015
InSite Vision (ISV) Reports Second Quarter 2015 Financial Results 8/12/2015
CMC Biologics Enters Into Agreement With The PATH Malaria Vaccine Initiative For Accelerated Development And Manufacturing Of Monoclonal Antibodies 8/12/2015
Japan Grants Safety Clearance To Pluristem Therapeutics (PSTI)'s PLX-PAD Cells For Use In Clinical Trials 8/12/2015
Immune Design Corporation (IMDZ) Announces Phase II Cancer Immunotherapy Trial Collaboration 8/12/2015
RXi Pharmaceuticals (RXII) Reports Second Quarter 2015 Financial Results And Business Highlights 8/12/2015
Soligenix (SNGX) Announces Recent Highlights and Second Quarter 2015 Financial Results 8/12/2015
Ardelyx (ARDX) Reports Second Quarter 2015 Financial Results 8/12/2015
Celator Pharmaceuticals, Inc. Announces Second Quarter 2015 Financial Results And Business Update 8/12/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Publication Elaborates On TB4's Effects On Dry Eye Syndrome And Other Potential Ophthalmic Disorders 8/12/2015
Tobira Therapeutics Inc. Reports Second Quarter 2015 Financial Results 8/12/2015
AbbVie (ABBV) Release: Phase 2 Study Of Venetoclax In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia With 17p Deletion Meets Primary Endpoint 8/12/2015
BioClin Therapeutics Initiates Phase 2 Clinical Trial Evaluating B-701 For Treatment Of Urothelial Cell Carcinoma 8/12/2015
BrainStorm Cell Therapeutics Inc. Announces Completion Of Enrollment In Phase 2 Clinical Trial Of NurOwn in ALS 8/11/2015
BioSpecifics Technologies Corporation (BSTC) Reports Second Quarter 2015 Financial Results 8/11/2015
Anthera Pharmaceuticals, Inc. (ANTH) Reports 2015 Second Quarter And Operational Update 8/11/2015
Cara Therapeutics, Inc. (CARA) Reports Second Quarter 2015 Financial Results 8/11/2015
Celldex (CLDX) Reports Second Quarter 2015 Results 8/11/2015
Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2015 Operational And Financial Results 8/11/2015
Trevena, Inc. (TRVN) Reports Second Quarter 2015 Financial Results And Provides A Corporate Update 8/11/2015
BioTime (BTX) Reports Second Quarter 2015 Results And Recent Developments 8/11/2015
Threshold Pharmaceuticals, Inc. (THLD) And ATOMIC Initiate First Phase 2 Clinical Trial Of Tarloxotinib Bromide (TH-4000) In Patients With Advanced EGFR-Mutant, T790M-Negative Non-Small Cell Lung Cancer (NSCLC) 8/11/2015
AEterna Zentaris (AEZS) Announces Data And Safety Monitoring Board Scheduled To Complete Second Interim Analysis Of The ZoptEC Phase 3 Trial In Endometrial Cancer In Early October 8/11/2015
Puma Biotech (PBYI) Reports Second Quarter 2015 Financial Results 8/11/2015
Ocular Therapeutix (OCUL) Reports Second Quarter 2015 Financial Results 8/11/2015
Ignyta (RXDX) Announces Second Quarter 2015 Company Highlights And Financial Results 8/11/2015
Discovery Laboratories (DSCO) Provides Business Update And Reports Second Quarter 2015 Financial Results 8/11/2015
Omeros Corporation (OMER) Reports Second Quarter 2015 Financial Results 8/11/2015
Lion Biotechnologies, Inc. Announces Second Quarter 2015 Financial Results 8/11/2015
Merrimack (MACK) Reports Second Quarter 2015 Financial Results 8/11/2015
Asterias Biotherapeutics Reports Second Quarter Results 8/11/2015
Portage Biotech's Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million 8/11/2015
Novavax (NVAX) Announces Positive Top-Line Data From Phase 2 RSV F-Protein Vaccine Clinical Trial In Older Adults 8/11/2015
BioClin Therapeutics Initiates Phase 2 Clinical Trial Evaluating B-701 For Treatment Of Urothelial Cell Carcinoma 8/11/2015
Adynxx Reports Positive Results For Phase 2b Study Of AYX1 8/11/2015
Karyopharm (KPTI) Tanks After Cancer Drug Trial Patients Get Sepsis 8/10/2015
Bay Area's XOMA (US) LLC (XOMA) to Cut Jobs and Change Focus in Light of Q2 Filings and Stock Drop 8/10/2015
Pluristem Therapeutics (PSTI) In Key Discussions With Europe's Adaptive Pathways Group On Phase II Protocol In Critical Limb Ischemia 8/10/2015
KaloBios Pharmaceuticals, Inc. (KBIO) Reports Second Quarter Financial Results And Provides Clinical Update 8/10/2015
AVEO Oncology (AVEO) Reports Second Quarter 2015 Financial Results 8/10/2015
MabVax Therapeutics Holdings Provides Corporate Update And Reports Second Quarter 2015 Financial Results 8/10/2015
Verastem, Inc. (VSTM) Reports Second Quarter 2015 Financial And Corporate Results 8/10/2015
Celsion Corporation (CLSN) Reports Second Quarter 2015 Financial Results And Provides Business Update 8/10/2015



//-->